The therapeutics of immunity of " adopt a young relative of cancer "

A new research has been started, studying a purpose is to realize the immune cell that uses patient oneself to treat cancer, customarily of this research domain is called therapeutics of immunity of adopt a young relative.

A new research has been started, studying a purpose is to realize the immune cell that uses patient oneself to treat cancer, customarily of this research domain is called " of therapeutics of immunity of " adopt a young relative.

Center of cancer of Ireland of hospital of university of gram Li Fulan (the item that the JulianA.Kim of *) accepted this to be aided financially by academy of American national sanitation, basically choose those who be engaged in T cell and use at treating skin cancer (melanin tumour ** ) with breast cancer. The element that studies the title of the project is therapeutics of immunity of "T cell adopt a young relative learns to consider, "Study funds is 660 thousand U.S. dollor, whole research time is 5 years.

Be in clinical in the research before, although use human body to organize the level that has study in the lab, investigator identifies what basically be engaged in cell of the T in patient lymph node and capture, pass the 1 time to 2 weeks to come in the lab enlarge increases a cell. The molecular reagent of cell of T of activation of in order to is element of the interpose between leucocyte - 2 with the antibody that fights CD3 (*** ) .

This one clinical the research before will conduce to how is investigator control chosen effectively and obtain T cell, t cell will be handled in special cell undertake growth in equipment. The T cell after activation will be guided afresh inside the body of identical patient, guide the immune system inside patient system to attack tumor thereby.

According to the view of Kim, I period considers to will 20 patients are participated in. "If these experiment prooves are valid, so the cancer that we can take the method of a few likeness to treat other type. "Kim say.